Iatrogenic and toxic myopathies

Muscle and Nerve

Volumn 27, Issue 2, 2003, Pages 142-156

  Sieb, Joern P ^a   Gillessen, Thomas ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Agent myopathy; Alcohol induced; Drug effects; Lipid lowering; Myopathies; Steroid myopathy; Zidovudine

Indexed keywords

ALCOHOL; AMINOCAPROIC ACID; AMIODARONE; CERIVASTATIN; CHLOROQUINE; CLOFIBRATE; CYCLOSPORIN; DIDANOSINE; DILTIAZEM; ERYTHROMYCIN; FIALURIDINE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GERMANIUM; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MEPACRINE; MEVINOLIN; NICOTINIC ACID; ORGANOPHOSPHATE; PAMAQUINE; PERHEXILINE MALEATE; PRAVASTATIN; SIMVASTATIN; SNAKE VENOM; TOXIN; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ALCOHOLISM; ATAXIA; CHEMICAL ANALYSIS; CORNEA INJURY; DEATH; DOSE TIME EFFECT RELATION; FATALITY; FATIGUE; HUMAN; HYPOKALEMIA; HYPOTHYROIDISM; IATROGENIC DISEASE; LACTIC ACIDOSIS; LIVER DISEASE; LIVER FAILURE; LIVER TOXICITY; MITOCHONDRIAL MYOPATHY; MORPHOLOGY; MUSCLE CRAMP; MUSCLE FUNCTION; MUSCLE NECROSIS; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; MYOPATHY; MYOSITIS; NEUROPATHY; NONHUMAN; OPPORTUNISTIC INFECTION; PANCREATITIS; PARALYSIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RETINA MACULA DEGENERATION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TREMOR; WASTING SYNDROME;

HUMANS; IATROGENIC DISEASE; MUSCULAR DISEASES; PHARMACEUTICAL PREPARATIONS; TOXINS, BIOLOGICAL;

EID: 0037309539     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.10244     Document Type: Review

References (166)

1. Haff disease associated with eating buffalo fish-United States, 1997. MMWR. Morbid Mortal Wkly Rep 1998;47:1091-1093.
2. Alejandro DS, Petersen J. Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine. J Am Soc Nephrol 1994;5:153-160.
3. Anderson NE, Lynch NM, O'Brien KP. Disabling neurological complications of amiodarone. Aust NZ J Med 1985;15:300-304.
4. Authier FJ, Cherin P, Creange A, Bonnotte B, Ferrer X, Abdelmoumni A, Ranoux D, Pelletier J, Figarella-Branger D, Granel B, Maisonobe T, Coquet M, Degos JD, Gherardi RK. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001;124:974-983.
5. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann lntern Med 1988;109:682-683.
6. Bardosi A, Dickmann U. Necrotizing myopathy with paracrystalline inclusion bodies in hypervitaminosis E. Acta Neuropathol (Berl) 1987;75:166-172.
7. Barlay CL, McLean M, Hagen N, Brownell AKW, MacRac ME. Severe phenytoin hypersensitivity with myopathy: a case report. Neurology 1992;42:2303.
8. Basser LS. Purgatives and periodic paralysis. Med J Aust 1979;1:47-48.
9. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology 1997; 48:1234-1238.
10. Bennett HS, Spiro AJ, Pollack MA, Zucker P. Ipecac-induced myopathy simulating dermatomyositis. Neurology 1982;32: 91-94.
11. Bermingham RP, Whitsitt TB, Smart ML, Nowak DP, Scalley RD. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am J Health Syst Pharm 2000;57:461-464.
12. Bettendorf U, Neuhaus R. Penicillamin-induzierte Polymyositis. Dtsch Med Wochenschr 1974;99:2522-2525.
13. Blackburn WD Jr, Eosinophilia myalgia syndrome. Semin Arthritis Rheum 1997;26:788-793.
14. Boger RH. Drug interactions of the statins and consequences for drug selection. Int J Clin Pharmacol Ther 2001; 39:369-382.
15. Bolton CF. Critical illness polyneuropathy. A useful concept. Muscle Nerve 1999;419-422.
16. Boot E, de Haan L. Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine, Psychopharmacology (Berl) 2000;150:347-348.
17. Bordet R, Caron J, Destee A, Dupuis B. Dystrophies musculaires progressives et risques médicamenteux. Therapie 1994;49:129-132.
18. Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies, J Neurol Sci 1970;10:107-131.
19. Breil M, Chariot P. Muscle disorders associated with cyclosporine treatment. Muscle Nerve 1999;22:1631-1636.
20. Buchholz U, Mouzin E, Dickey R, Moolenaar R, Sass N, Mascola L. Haff disease: from the Baltic Sea to the U.S. shore. Emerg Infect Dis 2000;6:192-195.
21. Carmichael AJ, Martin AM. Acute painful proximal myopathy associated with nalidixic acid. BMJ 1988;297:742.
22. Cervello A, Alfaro A, Chumillas MJ. Hypokalemic myopathy induced by Giardia lamblia. N Engl J Med 1993;329:210-211.
23. Chappel R, Willems J. D-penicillamine-induced myositis in rheumatoid arthritis. Clin Rheumatol 1996;15:86-87.
24. Chemali KR, Suarez JI, Katirji B. Acute hypokalemic paralysis associated with long-term lithium therapy. Muscle Nerve 2001;24:297-298.
25. Choucair AK, Ziter FA. Pentazocine abuse masquerading as familial myopathy. Neurology 1984;34:524-527.
26. Cirigliano G, Della RA, Tavoni A, Viacava P, Bombardieri S. Polymyositis occurring during alpha-interferon treatment for malignant melanoma: a case report and review of the literature. Rheumatol Int 1999;19:65-67.
27. Clouston PD, Donnelly PE. Acute necrotising myopathy associated with amiodarone therapy. Aust NZ J Med 1989;19: 483-485.
28. Comi G, Testa D, Cornelio F, Comola M, Canal N. Potassium depletion myopathy: a clinical and morphological study of six cases. Muscle Nerve 1985;8:17-21.
29. Costa-Jussà FR, Guevara A, Brook GA, Duchen LW, Jacobs JM. Changes in denervated skeletal muscle of amiodaronefed mice. Muscle Nerve 1988;11:627-637.
30. Crayton H, Bohlmann T, Sufit R, Graziano FM. Drug induced polymyositis secondary to leuprolide acetate (Lupron) therapy for prostate carcinoma. Clin Exp Rheumatol 1991;9:525-528.
31. Dalakas MC, Illa I, Pczeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322:1098-1105.
32. Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol 2000;17:64-69.
33. Drutz DJ, Fan JH, Tai TY, Cheng JT, Hsieh WC. Hypokalemic rhabdomyolysis and myoglobinuria following amphotericin B therapy. JAMA 1970;211:824-826.
34. Ducloux D, Schuller V, Bresson-Vautrin C, Chalopin JM. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol Dial Transplant 1997;12:2389-2392.
35. Estes ML, Ewing-Wilson D, Chou SM, Mitsumoto H, Hanson M, Shirey E, Ratliff NB. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987;82:447-455.
36. Estruch R, Nicolás JM, Villegas E, Junqué A, Urbano-Márquez A. Relationship between ethanol-related diseases and nutritional status in chronically alcoholic men. Alcohol Alcoholism 1993;28:543-550.
37. Estruch R, Sacanella E, Fernandez-Sola J, Nicolas JM, Rubin E, Urbano-Marquez A. Natural history of alcoholic myopathy: a 5-year study. Alcohol Clin Exp Res 1998;22:2023-2028.
38. Famularo G, Corsi FM, Giacanelli M. Iatrogenic worsening of hypokalemia and neuromuscular paralysis associated with the use of glucose solutions for potassium replacement in a young woman with licorice intoxication and furosemide abuse, Acad Emerg Med 1999;6:960-964.
39. Fardeau M, Tomé FM, Simon P. Muscle and nerve changes induced by perhexiline maleate in man and mice, Muscle Nerve 1979;2:24-36.
40. Fernández-Solà J, Estruch R, Urbano-Márquez A. Alcohol and heart muscle disease. Addiction Biol 1997;2:9-17.
41. Fernandez-Sola J, Junyent JM, Urbano-Marquez A. Alcoholic myopathies. Curr Opin Neurol 1996;9:400-405.
42. , Fernandez Sola J, Sacanella E, Estruch R, Nicolas JM, Grau JM, Urbano-Marquez A. Significance of type II fiber atrophy in chronic alcoholic myopathy. J Neurol Sci 1995;130:69-76.
43. Fernando RR, Itabashi H, Louie J, Anderson T, Narahara KA. Amiodarone toxicity: myopathy and neuropathy. Am Heart J 1990;119:1223-1225.
44. Finsterer J, Hess B, Jarius C, Stollberger C, Budka H, Mamoli B. Malnutrition-induced hypokalemic myopathy in chronic alcoholism. J Toxicol Clin Toxicol 1998;36:369-373.
45. Firn, D. Bayer warns on profits after drug's withdrawal, Financial Times (European edition), 9 August 2001.
46. Fontiveros ES, Cumming WJ, Hudgson P. Procainamide-induced myositis. J Neurol Sci 1980;45:143-147.
47. Forfar JC, Brown GJ, Cull RE. Proximal myopathy during beta-blockade. BMJ 1979;2:1331-1332.
48. Franca FO, Benvenuti LA, Fan HW, Dos Santos DR, Hain SH, Picchi-Martins FR, Cardoso JL, Kamiguti AS, Theakston RD, Warrell DA. Severe and fatal mass attacks by 'killer' bees (Africanized honey bees-Apis mellifera scutellata) in Brazil: clinicopathological studies with measurement of serum venom concentrations. QJ Med 1994;87:269-282.
49. Gala S, Katelaris CH. Rhabdomyolysis due to redback spider envenomation. Med J Aust 1992;157:66.
50. Garlepp MJ. Immunogenetics of inflammatory myopathies. Baillieres Clin Neurol 1993;2:579-597.
51. Gherardi RK, Coquet M, Cherin P, Authier FJ, Laforet P, Belec L, Figarella-Branger D, Mussini JM, Pellissier JF, Fardeau M. Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Francaise contre les Myopathies (AFM). Lancet 1998;352: 347-352.
52. Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier JF, Chariot P, Authier FJ. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminum hydroxide in muscle. Brain 2001;124: 1821-1831.
53. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999;22: 295-297.
54. Goebel HH, Kominami E, Neuen-Jacob E, Wheeler RB. Morphological studies on CLN2. Eur J Paediatr Neurol 2001; 5(suppl A):203-207.
55. Goodfellow R. Proximal myopathy during beta-blockade. BMJ 1980;280:399-400.
56. Greenblatt DJ, Allen MD. Intramuscular injection-site complications. JAMA 1978;240:542-544.
57. Gruberg L, Har-Zahav Y, Agranat O, Freimark D. Acute myopathy induced by colchicine in a cyclosporine treated heart transplant recipient: possible role of the multidrug resistance transporter. Transplant Proc 1999;31:2157-2158.
58. Gutmann L. Critical illness neuropathy and myopathy. Arch Neurol 1999;56:527-528.
59. Halbig L, Gutmann L, Goebel HH, Brick JF, Schochet S. Ultrastructural pathology in emetine-induced myopathy. Acta Neuropathol (Berl) 1988;75:577-582.
60. Haller RG, Carter NW, Ferguson E, Knochel JP. Serum and muscle potassium in experimental alcoholic myopathy. Neurology 1984;34:529-532.
61. Harney J, Glasberg MR. Myopathy and hypersensitivity to phenytion. Neurology 1983;33:790-791.
62. Hawkins RA, Eckhoff PJ Jr, MacCarter DK, Harmon CE. Cimetidine and polymyositis. N Engl J Med 1983;309:187-188.
63. Hengstman GJ, Vogels OJ, ter Laak HJ, de Witte T, van Engelen BG. Myositis during long-term interferon-alpha treatment. Neurology 2000;54:2186.
64. Higuchi I, Izumo S, Kuriyama M, Suehara M, Nakagawa M, Fukunaga H, Osame M, Ohtsubo S, Miyata K. Germanium myopathy: clinical and experimental pathological studies. Acta Neuropathol (Berl) 1989;79:300-304.
65. Hirano M, Ott BR, Raps EC, Minetti C, Lennihan L, Libbey NP, Bonilla E, Hays AP. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1999;42:2082-2087.
66. Hodak E, David M, Gadoth N, Sandbank M. Etretinate-induced skeletal muscle damage. Br J Dermatol 1987;116: 623-626.
67. Hodak E, Gadoth N, David M, Sandbank M. Muscle damage induced by isotretinoin. BM J 1986;293:425-426.
68. Hruban Z. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ Health Perspect 1984;55:53-76.
69. Hughes JT, Esiri M, Oxbury JM, Whitty CW. Chloroquine myopathy. QJ Med 1971;40:85-93.
70. Jagose JT, Bailey RR. Muscle weakness due to colchicine in a renal transplant recipient. NZ Med J 1997;110:343.
71. Jarvis JQ, Hammond E, Meier R, Robinson C. Cobalt cardiomyopathy. A report of two cases from mineral assay laboratories and a review of the literature. J Occup Med 1992;34: 620-626.
72. Jenkins P, Emerson PA. Myopathy induced by rifampicin. BMJ 1981;283:105-106.
73. Jensen OB, Mosdal C, Reske-Nielsen E. Hypokalemic myopathy during treatment with diuretics. Acta Neurol Scand 1977;55:465-482.
74. Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJ Med 1998;91:393-399.
75. Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001;94:339-341.
76. Kanda F, Okuda S, Matsushita T, Takatani K, Kimura Ki KI, Chihara K. Steroid myopathy: pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 2001;56(suppl 1):24-28.
77. Kanda F, Takatani K, Okuda S, Matsushita T, Chihara K. Preventive effects of insulinlike growth factor-I on steroid- induced muscle atrophy. Muscle Nerve 1999;22:213-217.
78. Kane MJ, Silverman LR, Rand JH, Paciucci PA, Holland JF. Myonecrosis as a complication of the use of epsilon aminocaproic acid: a case report and review of the literature. Am J Med 1988;85:861-863.
79. Kao KC, Tsai YH, Lin MC, Huang CC, Tsao CT, Chen YC. Hypokalemic muscular paralysis causing acute respiratory failure due to rhabdomyolysis with renal tubular acidosis in a chronic glue sniffer. J Toxicol Clin Toxicol 2000;38:679-681.
80. Kaplinsky N, Pines A, Thaler M, Frankl O. Breast tumor and polymyositis following cimetidine therapy-a possible association. J Rheumatol 1982;9:156-157.
81. Karalliedde L, Henry JA. Effects of organophosphates on skeletal muscle. Hum Exp Toxicol 1992;12:289-296.
82. Koeffler HP, Haskell CM. Rhabdomyolysis as a complication of 5-azacytidine. Cancer Treat Rep 1978;62:573-574.
83. Kottlors M, Jaksch M, Ketelsen U-W, Weiner S, Glocker FX, Lücking C-H. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord 2001;11:757-759.
84. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med 1987;316:1562-1568.
85. Kuntzer T, Bogousslavsky J, Deruaz JP, Janzer R, Regli F. Reversible emetine-induced myopathy with ECG abnormalities: a toxic myopathy. J Neurol 1989;236:246-248.
86. Lacomis D. Anorexia nervosa. Brain Pathol 1996;6:535-536.
87. Lafair JS, Myerson RM. Alcoholic myopathy. With special reference to the significance of creatine phosphokinase. Arch Intern Med 1968;122:417-422.
88. Lam CW, Lau CH, Williams JC, Chart YW, Wong LJC. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997;156:562-564.
89. Langer T, Levy RI, Acute muscular syndrome associated with admission of clofibrate. N Engl J Med 1968;279:856.
90. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995;333:664-665.
91. Levy RJ, Sparano JA, Khan G. Rhabdomyolysis: an unusual complication of cytotoxic chemotherapy. Med Oncol 1995; 12:219-222.
92. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-422.
93. Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med 1989;86:481-483.
94. Long HJ, Diamond SS, Raflo CP, Burningham RA. Dose-response relationships of chronic adriamycin toxicity in rabbits. Eur J Cancer Clin Oncol 1984;20:129-135.
95. Lüllmann-Rauch R. Drug-induced lysosomal storage disorders. Lysosomes in applied biology and therapeutics. Volume 6. New York: North Holland; 1979. p 49-130.
96. Marigliano N, Castellano I, Sanchez O, Covarsi A. Cerivastatin-induced rhabdomyolisis in a patient with diabetic nephropathy. Am J Nephrol 2001;21:85.
97. Masini A, Scotti C, Calligaro A, Cazzalini O, Stivala LA, Bianchi L, Giovannini F, Ceccarelli D, Muscatello U, Tomasi A, Vannini V. Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage. J Neurol Sci 1999;166:131-140.
98. Massa R, Carpenter S, Holland P, Karpati G. Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation. Muscle Nerve .1992;15:1290-1298.
99. Mastroianni GM, d'Ettorre G, Forcina G, Lichtner M, Corpolongo A, Coletta S, Vullo V. Rhabdomyolysis after cerivastatin- gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia. AIDS 2001;15:820-821.
100. McCloskey JR, Chung MK. Quadriceps contracture as a result of multiple intramuscular injection. Am J Dis Child 1977;131:416-417.
101. Mebs D, Ownby CL. Myotoxic components of snake venoms: their biochemical and biological activities. Pharmacol Ther 1990;48:223-236.
102. Meltzer HY. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message? Psychopharmacology (Berl) 2000;150:349-350.
103. Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996;15:395-405.
104. Mercier G, Patry G. Quebec beer-drinkers' cardiomyopathy: clinical signs and symptoms. Can Med Assoc J 1967;97:884-888.
105. Mhiri C, Baudrimont M, Bonne G, Geny C, Degoul F, Marsac C, Roullet E, Gherardi R. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol 1991;29:606-614.
106. Miro O, Pedrol E, Casademont J, Garcia-Carrasco M, Sanmarti R, Cebrian M, Grau JM. Muscle involvement in rheumatoid arthritis: clinicopathological study of 21 symptomatic cases. Semin Arthritis Rheum 1996;25:421-428.
107. Mohamed SD, Chapman RS, Crooks J. Hypokalaemia, flaccid quadriparesis, and myoglobinuria with carbenoxolone (biogastrone). BMJ 1966;5503:1581-1582.
108. Mora C, Rodriguez ML, Navarro JF. Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin. Transplantation 2001;72:551.
109. Müller-Vahl H. Aseptische Gewebsnekrose: eine schwerwiegende Komplikation nach intramuskulärer Injektion. Dtsch Med Wochenschr 1984;109:786-792.
110. Murray SS, Kramllnger KG, McMichan JC, Mohr DN. Acute toxicity after excessive ingestion of colchicine. Mayo Clin Proc 1983;58:528-532.
111. Nadel SM, Jackson JW, Ploth DW. Hypokalemic rhabdomyolysis and acute renal failure. Occurrence following total parenteral nutrition. JAMA 1979;241:2294-2296.
112. O'Malley B. Carbimazole-indluced cramps. Lancet 1989;i:1456-1457.
113. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-1107.
114. Ori M, Ikeda H. Spider venoms and spider toxins. J Toxicol Toxin Rev 1998;17:405-426.
115. Page SR, Nussey SS. Myositis in association with carbimazole therapy. Lancet 1989;i:964.
116. Palakurthy PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med 1987; 147:881-884.
117. Papadimitriou A, Hadjigeorgiou GM, Tsairis P, Papadimitriou E, Ouzounelli C, Ouzounellis T. Myoglobinuria due to quail poisoning. Eur Neurol 1996;36:142-145.
118. Papadimitriou A, Servidei S. Late onset lipid storage myopathy due to multiple acyl CoA dehydrogenase deficiency triggered by valproate. Neuromuscul Disord 1991;1:247-252.
119. Pasquier E, Genereau T, Baudrimont M, Cabane J, Biour M, Imbert JC. Biopsy-proven myositis with microvasculitis in association with carbimazole. Lancet 1991;338:1082-1083.
120. Pearn J. Neurology of ciguatera. J Neurol Neurosurg Psychiatry 2001;70:4-8.
121. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-75.
122. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. Am J Cardiol 1999;83:1146.
123. Posada DLP, Philen RM, Schurz H, Hill RH Jr, Gimenez RO, Gomez DLC, Kilbourne EM, Abaitua I. Epidemiologic evidence for a new class of compounds associated with toxic oil syndrome. Epidemiology 1999;10:130-134.
124. Preedy VR, Paice A, Mantle D, Dhillon AS, Palmer TN, Peters TJ. Alcoholic myopathy: biochemical mechanisms. Drug Alcohol Depend 2001;63:199-205.
125. Rana SS, Giuliani MJ, Oddis CV, Lacomis D. Acute onset of colchicine myonenropathy in cardiac transplant recipients: case studies of three patients. Clin Neurol Neurosurg 1997; 99:266-270.
126. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988;109:597-598.
127. Richards AJ. Hydroxychloroquine myopathy. J Rheumatol 1998;25:1642-1643.
128. Rizzi D, Basile C, Di Maggio A, Sebastio A, Introna F Jr, Rizzi R, Scatizzi A, De Marco S, Smialek JE. Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis. Nephrol Dial Transplant 1991;6:939-943.
129. Rodriguez ML, Mora C, Navarro JF. Cerivastatin-induced rhabdomyolysis. Ann Intern Med 2000;132:598.
130. Rygnestad T, Kvam AM. Streptococcal myositis and tissue necrosis with intramuscular administration of diclofenac (Voltaren). Acta Anaesthesiol Scand 1995;39:1128-1130.
131. Sacanella E, Fernandez-Sola J, Cofan M, Nicolas JM, Estruch R, Antunez E, Urbano-Marquez A. Chronic alcoholic myopathy: diagnostic clues and relationship with other ethanol-related diseases. QJ Med 1995;88:811-817.
132. Saito T, Tsuboi Y, Fujisawa G, Sakuma N, Honda K, Okada K, Saito K, Ishikawa S, Saito T. An autopsy case of licorice- induced hypokalemic rhabdomyolysis associated with acute renal failure: special reference to profound calcium deposition in skeletal and cardiac muscle. Nippon Jinzo Gakkai Shi 1994;36:1308-1314.
133. Scatizzi A, Di Maggio A, Rizzi D, Sebastio AM, Basile C. Acute renal failure due to tubular necrosis caused by wildfowl-mediated hemlock poisoning. Ren Fail 1993;15:93-96.
134. Scelsa SN, Simpson DM, McQuistion HI., Fineman A, Ault K, Reichler B. Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology 1996;47:1518-1523.
135. Semino-Mora C, Leon-Monzon M, Dalakas MC. Mitochondrial and cellular toxicity induced by fialuridine in human muscle in vitro. Lab Invest 1997;76:487-495.
136. Seymour BD, Rubinger M. Rhabdomyolysis induced by epsilon-aminocaproic acid. Ann Pharmacother 1997;31:56-58.
137. Shergy WJ, Caldwell DS. Polymyositis after propylthiouracil treatment for hyperthyroidism. Ann Rheum Dis 1988;47: 340-343.
138. Shinde A, Nakano S, Abe M, Kohara N, Akiguchi I, Shibasaki H. Accumulation of microtubule-based motor protein in a patient with colchicine myopathy. Neurology 2000;55:1414-1415.
139. Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 1997;20:316-322.
140. Silva OE, Peralta Rosado HR, Valero EC, Sadowinski E, Magana Serrano JA. A case of amiodarone and neuromyopathy. Rev Invest Clin 1997;49:135-139.
141. Sitwell LD, Weinshenker BG, Monpetit V, Reid D. Complete ophthalmoplegia as a complication of acute corticosteroid-and pancuronium associated myopathy. Neurology 1991;41:921-922.
142. Solomon M. Haff disease. Arch Intern Med 1990;150:683.
143. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000;27:2927-2931.
144. Stommel EW, Jenkyn LR, Parsonnet J. Another case of polymyositis after ciguatera toxin exposure. Arch Neurol 1993; 50:571.
145. Stommel EW, Parsonnet J, Jenkyn LR. Polymyositis after ciguatera toxin exposure. Arch Neurol 1991;48:874-877.
146. Sugita H, Higuchi I, Sano M, Ishiura S. Trial of a cysteine proteinase inhibitor, EST, in experimental chloroquine mypoathy in rats. Muscle Nerve 1987;10:516-523.
147. Tågerud S, Jirmanová I, Libelius R. Biochemical and ultrastructural effects of chloroquine on horseradish peroxidase uptake and lysosomal enzyme activities in innervated and denervated mouse skeletal muscle. J Neurol Sci 1986;75: 159-171.
148. Tao S-H. Hazard assessment of germanium supplements. Reg Toxicol Pharmacol 1997;25:211-219.
149. Tapal MF. Colchicine myopathy. Scand J Rheumatol 1996; 25:105-106.
150. Teicher A, Rosenthal T, Kissin E, Sarova I. Labetalol-induced toxic myopathy. BMJ 1981;282:1824-1825.
151. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J.
152. Tomlinson IW, Rosenthal FD. Proximal myopathy after perhexiline maleate treatment. BMJ 1977;1:1319-1320.
153. Tun NZ, Andermann F, Carpenter S, Karpati G. Antiepileptic drug myopathy. Neurology 1994;44:777-778.
154. Urbano-Márquez A, Estruch R, Fernández-Solá J, Nicolás JM, Paré JC, Rubin E. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 1995; 274:149-154.
155. Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau JM, Mont L, Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989;320:409-415.
156. Vandenbergh PYK, Guettat L, Berg BCV, Martin JJ. Focal myopathy associated with chronic intramuscular injection of piritramide. Muscle Nerve 1997;20:1598-1600.
157. Vanin JR. Ipecac abuse danger. J Am Coll Health 1992;40:237-238.
158. Vetter RS, Visscher PK, Camazine S. Mass envenomations by honey bees and wasps. West J Med 1999;170:223-227.
159. Victor M, Sieb JP. Myopathies due to drugs, toxins, and nutritional deficiency. In: Engel AG, Franzini-Armstrong C, editors. Myology. Volume 2. Basic and clinical. New York: McGraw-Hill; 1994. p 1697-1725.
160. Waclawik AJ, Lindal S, Engel AG. Experimental lovastatin myopathy. J Neuropathol Exp Neurol 1993;52:542-549.
161. Watson AJ, Dalbow MH, Stachura I, Fragola JA, Rubin MF, Watson RM, Bourke E. Immunologic studies in cimetidine-induced nephropathy and polymyositis. N Engl J Med 1983;308:142-145.
162. Weber M, Diener HC, Voit T, Neuen-Jacob E. Focal myopathy induced by chronic heroin injection is reversible. Muscle Nerve 2000;23:274-277.
163. Whisnant JP, Espinosa RE, Kierland RR, Lambert EH. Chloroquine neuromyopathy. Proc Mayo Clin 1963;38:501.
164. Willis JK, Tilton AH, Harkin JC, Boineau FG. Reversible myopathy due to labetalol. Pediatr Neurol 1990;6:275-276.
165. Winter SS, Chaffee S, Kahler SG, Graham ML. Epsilon-aminocaproic acid-associated myopathy in a child. J Pediatr Hematol Oncol 1995;17:53-55.
166. Wolf S, Goldberg LS, Verity MA. Neuromyopathy and periarteriolitis in patient receiving levodopa. Arch Intern Med 1976;136:1055.